Latest filing published 20 Nov 2023 for Rani Therapeutics Holdings, Inc., €912.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +1.5%Entry US$2.02 · Close at T+365 US$2.05
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Maulik Nanavaty: trading record in brief
Maulik Nanavaty (senior executive) discloses dealings in 2 companies, chiefly Boston Scientific Corp and Rani Therapeutics Holdings, Inc. Over a trading history stretching from 30 October 2011 to 16 November 2023, the count stands at 194 filings.
Market trades split into 1 purchase (€912) and 22 sales (€13.0M). Netting one side against the other leaves €13.0M of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 76 share grants and 93 option exercises. So far in 2023, the count stands at 1 purchase and no sales.
The record was last updated on 20 November 2023 with an open-market purchase (€912) in Rani Therapeutics Holdings, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Maulik Nanavaty
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 500 shares@ US$1.98100.0% of flowClass A Common StockSEC:0000950170-23-064982:0Canonical exit: 14 Feb 2024 (T+90)
- 564 shares@ US$44.170.1% of flowCommon StockSEC:0001225208-22-003865:1
- 1,630 shares0Common StockSEC:0001225208-22-003865:0
- 593 shares@ US$42.550.1% of flowCommon StockSEC:0001225208-22-003085:1
- 1,714 shares0Common StockSEC:0001225208-22-003085:0
- 750 shares@ US$42.830.2% of flowCommon StockSEC:0001225208-22-002924:1
- 616 shares@ US$42.550.1% of flowCommon StockSEC:0001225208-22-002924:3
- 1,779 shares0Common StockSEC:0001225208-22-002924:2
- 2,166 shares0Common StockSEC:0001225208-22-002924:0
- 575 shares@ US$44.010.1% of flowCommon StockSEC:0001225208-22-002681:1
- 1,661 shares0Common StockSEC:0001225208-22-002681:0
- 11,017 shares0Class A Common StockSEC:0001209191-22-007638:0
- 2,346 shares@ US$42.480.5% of flowCommon StockSEC:0001225208-22-000115:1
- 6,175 shares0Common StockSEC:0001225208-22-000115:0
- 78,192 shares@ US$42.5931100.0% of flowCommon StockSEC:0001225208-21-008788:0
- 1,629 shares0Common StockSEC:0001225208-21-004223:0
- 564 shares@ US$38.780.1% of flowCommon StockSEC:0001225208-21-004223:1
- 593 shares@ US$38.030.1% of flowCommon StockSEC:0001225208-21-003524:1
- 652 shares@ US$39.200.1% of flowCommon StockSEC:0001225208-21-003524:3
- 1,713 shares0Common StockSEC:0001225208-21-003524:0
- 1,883 shares0Common StockSEC:0001225208-21-003524:2
- 615 shares@ US$37.520.1% of flowCommon StockSEC:0001225208-21-003178:1
- 1,778 shares0Common StockSEC:0001225208-21-003178:0
- 575 shares@ US$38.390.1% of flowCommon StockSEC:0001225208-21-002706:1
- 1,661 shares0Common StockSEC:0001225208-21-002706:0
25 of 194 declarations
